
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
| Company |
|---|
Orakl Oncology works on a large cohort of patient-derived organoids (PDO) to predict clinical outcomes of patients and derisk clinical trials. We are looking for a dynamic and motivated Lab Technician to help us execute large-scale drug screening assays on our semi-automated platform, either for internal or external projects. In this position, you will:
Actively participate in our commercial contracts: you will take care of numerous PDOs of interest and perform drug screening assays to generate high-quality, robust datasets. These results will be leveraged by our data science and computational biology teams to deliver actionable insights and decision-support data to our partners.
Work on the expansion of the Orakl biobank: you will work on patient specimens and organoid cell lines to increase the amount of data collected, thus improving our understanding of cancer.
Contribute to the optimisation procedures at Orakl: you will bring new ideas and approaches to improve automation and accelerate workflows in both 3D cell culture and drug screening experiments.
Ensure smooth laboratory operations: you will play a key role in laboratory maintenance, documentation, and traceability of activities, while proactively anticipating the needs for consumables and reagents.### Need-to-have
BSc (or equivalent degree such as BTS, BUT, Licence) in cellular biology, biotechnology or any related discipline.
Hands-on experience in mammalian cell culture, 3D cell culture and preferably organoid culture.
Hands-on experience in drug screening assays or viability assessment assay.
Exceptional attention to detail and organisational rigour.
Flexibility, and a taste for overcoming operational challenges.
A genuine enthusiasm and passion for teamwork and learning.
As part of an international team, a good understanding of English and the ability to communicate in English are a plus
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Lab Case (Around 90 minutes) - You will be directly manipulating in our labs to demonstrate your ability to follow a specific protocol and to work under aseptic condtions.
Founder Interview: As final step of our recruitment process, you will meet the CTO of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.